#ydes

@zackssmallcap.bsky.social

2 months ago

#YDES: YD Biopharma Is An Integrated Biotechnology Company That Is Poised To Have A Transformational Year As It Expands Business Operations buff.ly/N2Wf4vW

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

2 months ago

#YDES is A Biotechnology Company on the Move buff.ly/N2Wf4vW

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of

#YDES YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

www.stocktitan.net/news/YDES/yd-bio-enters-...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Biotech maps 2026 push on eye disease therapies and cancer blood tests YD Bio completes key CMC work and DMFs, runs cancer tests in 46 U.S. states, eyes up to three 2026 acquisitions and new trials through 2027.

#YDES YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

www.stocktitan.net/news/YDES/yd-bio-limited...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a

#YDES YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

www.stocktitan.net/news/YDES/yd-bio-limited...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN YD Bio (Nasdaq: YDES) exhibited at the 9th Healthcare Expo Taiwan in Taipei from Dec 4–7, 2025, presenting its DNA methylation-based OkaiDx cancer detection platform, multi-biomarker early detection, next-generation precision diagnostics, and ophthalmology stem cell/exosome programs at Booth No. 4F, M1004.The company reported 1,500+ visitors and 541 on-site surveys over four days, held discussions with distributors from China, Hong Kong, Indonesia, and Dubai, and engaged hospital leaders about using EG BioMed US Inc.'s CLIA-certified, CAP-accredited U.S. lab as a global central lab for precision cancer testing.

#YDES YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

www.stocktitan.net/news/YDES/yd-bio-limited...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Nov 24th - #YDES #HSAI #VOR #SLRX #NXTC #MXL #ENLV #CLLS #BLFY #AEHL #MAGN #GNK #CMDB #BFLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics YD Bio (Nasdaq: YDES) announced U.S. ophthalmology regulatory and clinical milestones on Nov 24, 2025 that establish its first commercial entry into U.S. eye care and advance limbal stem cell (LSC) exosome therapeutics.Key achievements: Exovisse Contact Lenses received FDA 510(k) clearance as a Class II device; Exovisse Artificial Tears were developed in compliance with the FDA OTC Final Monograph M018 for nationwide OTC distribution; and YD Bio enrolled its LSC and LSC-derived exosomes in an FDA Drug Master File to support future therapeutics.

#YDES YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

www.stocktitan.net/news/YDES/yd-bio-limited...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring YD Bio (NasdaqGM: YDES) announced support for U.S. access to OkaiDx™, a cfDNA‑methylation blood test for post‑treatment breast cancer monitoring, now available through affiliate EG BioMed’s CLIA/CAP‑certified laboratory as a research‑use‑only (RUO) assay.The company will coordinate commercialization, researcher engagement and sample logistics to enable testing for research laboratories, academic groups and industry partners. Independent validation reported 95.1% accuracy, 89.4% sensitivity and 96.5% specificity. OkaiDx™ is not FDA cleared and is not intended to diagnose, treat, cure or prevent disease.

#YDES YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

www.stocktitan.net/news/YDES/yd-bio-and-eg-...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities YD Bio (Nasdaq: YDES) announced that its business partner EG BioMed achieved CAP accreditation for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600) on October 10, 2025. CAP accreditation, alongside existing CLIA certification, confirms laboratory quality standards and strengthens EG BioMed’s ability to deliver advanced laboratory-developed tests (LDTs) supporting YD Bio’s DNA methylation-based pancreatic and breast cancer detection programs in the U.S.YD Bio highlighted that this accreditation positions the companies to expand their diagnostic portfolio for early cancer detection and monitoring. EG BioMed’s Chief R&D Officer presented new circulating cell-free DNA biomarker findings at AACR (September 28–October 1, 2025) relevant to metastatic pancreatic cancer monitoring.

#YDES YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

www.stocktitan.net/news/YDES/yd-bio-busines...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results YD Bio Limited (NASDAQ:YDES) reported its H1 2025 financial results, marked by strategic developments despite financial headwinds. The company's net revenue decreased 9% to $204,007, while operating expenses increased significantly to $2.0 million, resulting in a net loss of $1.9 million.Key developments include securing $13.2 million in PIPE financing through a business combination with Breeze Holdings, advancing DNA methylation-based cancer detection technology, and expanding into ophthalmologic innovations. The company launched a pancreatic cancer screening LDT and plans to introduce a breast cancer recurrence monitoring LDT. Additionally, YD Bio is developing corneal stem-cell and exosome-based treatments for various eye conditions, with clinical trials planned for 2027.

#YDES YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

www.stocktitan.net/news/YDES/yd-bio-limited...

0 0 0 0

Michael Patrick S.Louis

@michael9011.bsky.social

9 months ago

“La pierre de touche du succès n'est pas que le problème soit difficile, mais qu'il soit différent de celui de la veille.” #Reilhac #Sansacdemarmiesse #Polminhac #Ydes #Anglardsdesalers #Saintmartinvalmeroux #Vézac #Neuvéglise #Saintpauldeslandes #Lanobre #Ytrac

1 0 0 0

Monumentum

@monumentum.fr

10 months ago

Eglise Saint-Georges à #Ydes (#Cantal) Eglise : classement par liste de 1862. Suite 👉 https://monumentum.fr/monument-historique/pa00093723/ydes-eglise-saint-georges

Eglise Saint-Georges à #Ydes (#Cantal) Eglise : classement par liste de 1862.
Suite 👉 monumentum.fr/monument-historique/pa00...

0 0 0 0